AMGN · News · 20260916N
Product / Drug Pipeline Progress
AMGEN INC · 2026-09-16 · Importance 49 · Surprise 66
Amgen highlighted progress in its IMDELLTRA small-cell lung cancer program, including clinical-trial improvements and reduced monitoring requirements. The company also provided updates on its MariTide obesity program and other late-stage pipeline assets. Amgen’s six key growth drivers recorded a 26% year-over-year increase in second-quarter product sales, although this metric is reported separately from the pipeline developments.